{"id": "article-134517_0", "title": "Vericiguat -- Continuing Education Activity", "content": "Vericiguat is a medication used to manage and treat heart failure with reduced ejection fraction (HFrEF). It is useful for chronic worsening heart failure and recently decompensated heart failure, high-risk heart failure with reduced ejection fraction, especially for patients who had been rehospitalized or are on intravenous diuretic therapy, or patients requiring urgent treatment for heart failure. Vericiguat does not prolong survival but prevents rehospitalization. This activity outlines the indications, mechanism of action, dose, and mode of administration by the interprofessional team, adverse effects, contraindications, monitoring parameters, and several trials to support the evidence of the drug's usefulness in HFrEF. It also highlights the role of an interprofessional team in managing patients with heart failure using vericiguat.", "contents": "Vericiguat -- Continuing Education Activity. Vericiguat is a medication used to manage and treat heart failure with reduced ejection fraction (HFrEF). It is useful for chronic worsening heart failure and recently decompensated heart failure, high-risk heart failure with reduced ejection fraction, especially for patients who had been rehospitalized or are on intravenous diuretic therapy, or patients requiring urgent treatment for heart failure. Vericiguat does not prolong survival but prevents rehospitalization. This activity outlines the indications, mechanism of action, dose, and mode of administration by the interprofessional team, adverse effects, contraindications, monitoring parameters, and several trials to support the evidence of the drug's usefulness in HFrEF. It also highlights the role of an interprofessional team in managing patients with heart failure using vericiguat."}
{"id": "article-134517_1", "title": "Vericiguat -- Continuing Education Activity", "content": "Objectives: Describe the indications of vericiguat as a novel agent for heart failure with a reduced ejection fraction. Review the potential adverse effects associated with the use of vericiguat. Explain the mechanism of action of vericiguat. Outline the dose of administering vericiguat and explain the importance of monitoring vitals after administration of the drug by the interprofessional team to help titration and decide the dose. Access free multiple choice questions on this topic.", "contents": "Vericiguat -- Continuing Education Activity. Objectives: Describe the indications of vericiguat as a novel agent for heart failure with a reduced ejection fraction. Review the potential adverse effects associated with the use of vericiguat. Explain the mechanism of action of vericiguat. Outline the dose of administering vericiguat and explain the importance of monitoring vitals after administration of the drug by the interprofessional team to help titration and decide the dose. Access free multiple choice questions on this topic."}
{"id": "article-134517_2", "title": "Vericiguat -- Indications", "content": "Vericiguat is a novel agent, an oral soluble guanylate cyclase stimulator used to treat\u00a0heart failure with reduced ejection fraction (HFrEF) patients. It is also useful for chronic heart failure with recently decompensated or worsening heart failure, high-risk heart failure with reduced ejection fraction, especially for\u00a0patients who had been rehospitalized or are on intravenous diuretic therapy, or patients requiring urgent treatment for heart failure. [1] [2]", "contents": "Vericiguat -- Indications. Vericiguat is a novel agent, an oral soluble guanylate cyclase stimulator used to treat\u00a0heart failure with reduced ejection fraction (HFrEF) patients. It is also useful for chronic heart failure with recently decompensated or worsening heart failure, high-risk heart failure with reduced ejection fraction, especially for\u00a0patients who had been rehospitalized or are on intravenous diuretic therapy, or patients requiring urgent treatment for heart failure. [1] [2]"}
{"id": "article-134517_3", "title": "Vericiguat -- Indications", "content": "Vericiguat was approved by the Food and Drug Administration (FDA) in January 2021. It can serve\u00a0as an add-on therapy for heart failure with reduced ejection fraction following worsening heart failure. Surprisingly, vericiguat has per patient per month budget impact of fewer than 10 cents, the reason being the reduction in HF hospitalizations and CV deaths. [3] [4]", "contents": "Vericiguat -- Indications. Vericiguat was approved by the Food and Drug Administration (FDA) in January 2021. It can serve\u00a0as an add-on therapy for heart failure with reduced ejection fraction following worsening heart failure. Surprisingly, vericiguat has per patient per month budget impact of fewer than 10 cents, the reason being the reduction in HF hospitalizations and CV deaths. [3] [4]"}
{"id": "article-134517_4", "title": "Vericiguat -- Indications", "content": "Based on the phase III VICTORIA (Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction)\u00a0trial results, the FDA approved vericiguat for patients with HFrEF. [5] VICTORIA\u00a0was a multi-centered, randomized, placebo-controlled, double-blind, pivotal phase III trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator vericiguat in subjects with heart failure with reduced ejection fraction. This clinical trial included 5050 patients. The intervention included a single daily dose of 10 mg vericiguat in addition to heart failure guideline therapy. Patients were followed up for 10.8 months. The primary outcome event was cardiovascular death and first heart failure hospitalization. In the trial conclusion, compared to placebo, vericiguat has a beneficial effect with a hazard ratio of 0.90 (95% CI: 0.82 \u2013 0.98; P=0.02) for either of the primary outcome events in patients with NTproBNP <8000 pg/ml. Also, the risk of primary outcome event in vericiguat compared to placebo in patients aged < 75 and >= 75 years was 0.84 and 1.04, respectively (P value=0.030). [1]", "contents": "Vericiguat -- Indications. Based on the phase III VICTORIA (Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction)\u00a0trial results, the FDA approved vericiguat for patients with HFrEF. [5] VICTORIA\u00a0was a multi-centered, randomized, placebo-controlled, double-blind, pivotal phase III trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator vericiguat in subjects with heart failure with reduced ejection fraction. This clinical trial included 5050 patients. The intervention included a single daily dose of 10 mg vericiguat in addition to heart failure guideline therapy. Patients were followed up for 10.8 months. The primary outcome event was cardiovascular death and first heart failure hospitalization. In the trial conclusion, compared to placebo, vericiguat has a beneficial effect with a hazard ratio of 0.90 (95% CI: 0.82 \u2013 0.98; P=0.02) for either of the primary outcome events in patients with NTproBNP <8000 pg/ml. Also, the risk of primary outcome event in vericiguat compared to placebo in patients aged < 75 and >= 75 years was 0.84 and 1.04, respectively (P value=0.030). [1]"}
{"id": "article-134517_5", "title": "Vericiguat -- Indications", "content": "According to ACC/AHA 2022 guidelines, heart failure(HF)\u00a0has been classified as stage A (at risk of HF), Stage B (Pre-HF), Stage C (Symptomatic HF), and Stage D (advanced HF). Vericiguat should be considered for patients with Stage C HFrEF(Structural heart disease with current or previous symptoms of HF). [6]", "contents": "Vericiguat -- Indications. According to ACC/AHA 2022 guidelines, heart failure(HF)\u00a0has been classified as stage A (at risk of HF), Stage B (Pre-HF), Stage C (Symptomatic HF), and Stage D (advanced HF). Vericiguat should be considered for patients with Stage C HFrEF(Structural heart disease with current or previous symptoms of HF). [6]"}
{"id": "article-134517_6", "title": "Vericiguat -- Indications", "content": "Researchers are awaiting the result of an ongoing trial of vericiguat for HFpEF to answer questions like the importance of measuring plasma or urinary cyclic GMP levels or whether atrial natriuretic peptide would be helpful. Assessment of nitric oxide level would be required to assess the best response of vericiguat. An important concern of combining vericiguat and sacubitril-valsartan (soluble guanylyl cyclase and particulate guanylyl cyclase) would have a synergistic effect, and the effect on adverse effect of hypotension or syncope is unanswered. [7]", "contents": "Vericiguat -- Indications. Researchers are awaiting the result of an ongoing trial of vericiguat for HFpEF to answer questions like the importance of measuring plasma or urinary cyclic GMP levels or whether atrial natriuretic peptide would be helpful. Assessment of nitric oxide level would be required to assess the best response of vericiguat. An important concern of combining vericiguat and sacubitril-valsartan (soluble guanylyl cyclase and particulate guanylyl cyclase) would have a synergistic effect, and the effect on adverse effect of hypotension or syncope is unanswered. [7]"}
{"id": "article-134517_7", "title": "Vericiguat -- Mechanism of Action", "content": "There are two forms of guanylate cyclase; one is a transmembrane receptor for natriuretic peptides, and the other is a soluble guanylate cyclase (sGC), a receptor for nitric oxide. Nitric oxide and natriuretic peptides indirectly increase phosphokinase G (PKG) levels through sGC by activating guanosine triphosphate to cyclic guanosine monophosphate (cGMP). The phosphokinase G causes cellular hyperpolarization and cardiac muscle relaxation. In patients with cardiovascular risk factors, the endothelium-generated reactive oxygen species decrease the nitric oxide levels and inactivate the sGC by removing the heme group from sGC leading to decreased PKG and impaired muscle relaxation resulting in stiffness. The transforming growth factor-beta produced by monocytes led to the conversion of fibroblasts into myofibroblasts, ultimately leading to collagen formation and stiffening of cardiac muscle. [1] [8]", "contents": "Vericiguat -- Mechanism of Action. There are two forms of guanylate cyclase; one is a transmembrane receptor for natriuretic peptides, and the other is a soluble guanylate cyclase (sGC), a receptor for nitric oxide. Nitric oxide and natriuretic peptides indirectly increase phosphokinase G (PKG) levels through sGC by activating guanosine triphosphate to cyclic guanosine monophosphate (cGMP). The phosphokinase G causes cellular hyperpolarization and cardiac muscle relaxation. In patients with cardiovascular risk factors, the endothelium-generated reactive oxygen species decrease the nitric oxide levels and inactivate the sGC by removing the heme group from sGC leading to decreased PKG and impaired muscle relaxation resulting in stiffness. The transforming growth factor-beta produced by monocytes led to the conversion of fibroblasts into myofibroblasts, ultimately leading to collagen formation and stiffening of cardiac muscle. [1] [8]"}
{"id": "article-134517_8", "title": "Vericiguat -- Mechanism of Action", "content": "The treatment of heart failure with nitric oxide generators is shown to have clinical benefits but is limited by the development of tolerance. Also, the reactive oxygen species decreases the sensitivity of soluble guanylate cyclase to nitric oxide. The soluble guanylate cyclase stimulators act by nitric oxide independent enhancement of soluble guanylate cyclase activity along with increased sensitivity of sGC to endogenous nitric oxide.", "contents": "Vericiguat -- Mechanism of Action. The treatment of heart failure with nitric oxide generators is shown to have clinical benefits but is limited by the development of tolerance. Also, the reactive oxygen species decreases the sensitivity of soluble guanylate cyclase to nitric oxide. The soluble guanylate cyclase stimulators act by nitric oxide independent enhancement of soluble guanylate cyclase activity along with increased sensitivity of sGC to endogenous nitric oxide."}
{"id": "article-134517_9", "title": "Vericiguat -- Mechanism of Action", "content": "Vericiguat stimulates soluble guanylate cyclase that activates the cGMP pathway independent of nitric oxide involvement. It also sensitizes soluble guanylate cyclase to nitric oxide by stabilizing nitric oxide binding to the binding site. In other words, vericiguat restores the cyclic guanosine monophosphate under low nitric oxide conditions and oxidative stress. [2] [9] [10] Compared to other nitro-vasodilators, vericiguat does not induce tolerance on long-term administrations. [7] An increase in cardiac output and cardiac index and a decrease in systemic vascular resistance has been noted with vericiguat at a 5.0 mg or higher dose. [11] [12]", "contents": "Vericiguat -- Mechanism of Action. Vericiguat stimulates soluble guanylate cyclase that activates the cGMP pathway independent of nitric oxide involvement. It also sensitizes soluble guanylate cyclase to nitric oxide by stabilizing nitric oxide binding to the binding site. In other words, vericiguat restores the cyclic guanosine monophosphate under low nitric oxide conditions and oxidative stress. [2] [9] [10] Compared to other nitro-vasodilators, vericiguat does not induce tolerance on long-term administrations. [7] An increase in cardiac output and cardiac index and a decrease in systemic vascular resistance has been noted with vericiguat at a 5.0 mg or higher dose. [11] [12]"}
{"id": "article-134517_10", "title": "Vericiguat -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption:\u00a0The bioavailability of vericiguat is 93% when taken with food. Food increases AUC (area under the curve- \u00a0total drug exposure across time) of vericiguat. Distribution: Vericiguat\u00a0has high plasma protein binding (98%) and is primarily bound to albumin. The\u00a0average\u00a0volume of distribution(Vd) is approximately 44\u00a0Liters.", "contents": "Vericiguat -- Mechanism of Action -- Pharmacokinetics. Absorption:\u00a0The bioavailability of vericiguat is 93% when taken with food. Food increases AUC (area under the curve- \u00a0total drug exposure across time) of vericiguat. Distribution: Vericiguat\u00a0has high plasma protein binding (98%) and is primarily bound to albumin. The\u00a0average\u00a0volume of distribution(Vd) is approximately 44\u00a0Liters."}
{"id": "article-134517_11", "title": "Vericiguat -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Vericiguat is metabolized primarily by\u00a0glucuronidation via\u00a0UGT1A9(uridine diphosphate-glucuronosyltransferase) and\u00a0UGT1A1 to form an inactive metabolite. The Cytochrome P450 system is responsible for <5% metabolism of vericiguat.", "contents": "Vericiguat -- Mechanism of Action -- Pharmacokinetics. Metabolism: Vericiguat is metabolized primarily by\u00a0glucuronidation via\u00a0UGT1A9(uridine diphosphate-glucuronosyltransferase) and\u00a0UGT1A1 to form an inactive metabolite. The Cytochrome P450 system is responsible for <5% metabolism of vericiguat."}
{"id": "article-134517_12", "title": "Vericiguat -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: The half-life is 30 hours in patients with heart failure. Clearance is approximately 1.6 L/h. Vericiguat is excreted primarily in urine as an inactive metabolite(53%). Vericiguat is also excreted as an unchanged drug in feces(43%). [9]", "contents": "Vericiguat -- Mechanism of Action -- Pharmacokinetics. Excretion: The half-life is 30 hours in patients with heart failure. Clearance is approximately 1.6 L/h. Vericiguat is excreted primarily in urine as an inactive metabolite(53%). Vericiguat is also excreted as an unchanged drug in feces(43%). [9]"}
{"id": "article-134517_13", "title": "Vericiguat -- Administration", "content": "An increase in cardiac output, an increase in heart rate of 4\u00a0to 10 beats per minute, and an increase in the cardiac index are observed in patients who received a single dose of 5\u00a0to 15 mg\u00a0per oral (PO). In addition, systemic vascular resistance has decreased from the baseline, thereby reducing blood pressure. However, the effect was inconsistent and not dose-dependent.", "contents": "Vericiguat -- Administration. An increase in cardiac output, an increase in heart rate of 4\u00a0to 10 beats per minute, and an increase in the cardiac index are observed in patients who received a single dose of 5\u00a0to 15 mg\u00a0per oral (PO). In addition, systemic vascular resistance has decreased from the baseline, thereby reducing blood pressure. However, the effect was inconsistent and not dose-dependent."}
{"id": "article-134517_14", "title": "Vericiguat -- Administration", "content": "The immediate-release form of the vericiguat showed a mean half-life (t1/2) of about 18\u00a0to 22 hours. There were no significant differences between single and multiple doses\u00a0regarding bioavailability, the area under the curve (AUC), and Cmax (maximum concentration). Absorption through percutaneous endoscopic gastrostomy (PEG) is reported to be faster when compared to oral administration. As discussed above, food increases the bioavailability of vericiguat and reduces the variability in the postprandial/fed state; hence medication\u00a0should be administered with food.\u00a0A single oral dose of 10 mg was well tolerated by healthy Japanese, Chinese and European subjects. [1] [11]", "contents": "Vericiguat -- Administration. The immediate-release form of the vericiguat showed a mean half-life (t1/2) of about 18\u00a0to 22 hours. There were no significant differences between single and multiple doses\u00a0regarding bioavailability, the area under the curve (AUC), and Cmax (maximum concentration). Absorption through percutaneous endoscopic gastrostomy (PEG) is reported to be faster when compared to oral administration. As discussed above, food increases the bioavailability of vericiguat and reduces the variability in the postprandial/fed state; hence medication\u00a0should be administered with food.\u00a0A single oral dose of 10 mg was well tolerated by healthy Japanese, Chinese and European subjects. [1] [11]"}
{"id": "article-134517_15", "title": "Vericiguat -- Administration", "content": "According to phase III of the VICTORIA Heart Failure with Reduced Ejection Fraction study, the dose of vericiguat can be increased from 2.5 mg to 10 mg depending on patient response. Phase II of the VITALITY Heart Failure with\u00a0Preserved Ejection Fraction study\u00a0reported that the dose could be titrated up to 15 mg. [9]", "contents": "Vericiguat -- Administration. According to phase III of the VICTORIA Heart Failure with Reduced Ejection Fraction study, the dose of vericiguat can be increased from 2.5 mg to 10 mg depending on patient response. Phase II of the VITALITY Heart Failure with\u00a0Preserved Ejection Fraction study\u00a0reported that the dose could be titrated up to 15 mg. [9]"}
{"id": "article-134517_16", "title": "Vericiguat -- Administration -- Use in Specific Patient Population", "content": "Patients with Hepatic Impairment: No dosage adjustment of\u00a0vericiguat is\u00a0advised in patients with mild hepatic impairment(Child-Pugh A) or moderate hepatic impairment (Child-Pugh B). Use of vericiguat should be avoided in\u00a0severe hepatic impairment(Child-Pugh C) as there are no studies conducted in these patient populations.", "contents": "Vericiguat -- Administration -- Use in Specific Patient Population. Patients with Hepatic Impairment: No dosage adjustment of\u00a0vericiguat is\u00a0advised in patients with mild hepatic impairment(Child-Pugh A) or moderate hepatic impairment (Child-Pugh B). Use of vericiguat should be avoided in\u00a0severe hepatic impairment(Child-Pugh C) as there are no studies conducted in these patient populations."}
{"id": "article-134517_17", "title": "Vericiguat -- Administration -- Use in Specific Patient Population", "content": "Patients with Renal Impairment: No dosage adjustment of\u00a0vericiguat is\u00a0suggested\u00a0in patients with eGFR \u226515 mL/min/1.73m2. However, the\u00a0use\u00a0of vericiguat has not been investigated in patients with eGFR <15 mL/min/1.73m2 or on dialysis. [13] Breastfeeding Considerations: Vericiguat has the\u00a0potential cause for serious adverse reactions in breastfed infants. Hence, breastfeeding is not recommended during treatment with vericiguat.", "contents": "Vericiguat -- Administration -- Use in Specific Patient Population. Patients with Renal Impairment: No dosage adjustment of\u00a0vericiguat is\u00a0suggested\u00a0in patients with eGFR \u226515 mL/min/1.73m2. However, the\u00a0use\u00a0of vericiguat has not been investigated in patients with eGFR <15 mL/min/1.73m2 or on dialysis. [13] Breastfeeding Considerations: Vericiguat has the\u00a0potential cause for serious adverse reactions in breastfed infants. Hence, breastfeeding is not recommended during treatment with vericiguat."}
{"id": "article-134517_18", "title": "Vericiguat -- Administration -- Use in Specific Patient Population", "content": "Pregnancy Considerations: Due to concerns for embryo-fetal toxicity and substantial fetal harm to the fetus,\u00a0vericiguat should not be administered to pregnant women or currently planning for pregnancy. [6]", "contents": "Vericiguat -- Administration -- Use in Specific Patient Population. Pregnancy Considerations: Due to concerns for embryo-fetal toxicity and substantial fetal harm to the fetus,\u00a0vericiguat should not be administered to pregnant women or currently planning for pregnancy. [6]"}
{"id": "article-134517_19", "title": "Vericiguat -- Adverse Effects", "content": "The most common adverse drug reactions of vericiguat\u00a0include\u00a0hypotension, syncope, and anemia. [2] Headache and postural dizziness reportedly could be due to vasodilation mediated by vericiguat. Diarrhea, nausea, and abdominal discomfort have been postulated due to smooth muscle relaxation. [11] Symptomatic hypotension, orthostatic hypotension, syncope, and anemia are some of the known side effects of vericiguat. [1] A mild increase in heart rate was observed, which\u00a0researchers considered the compensatory baroreflex due to vasodilation and blood pressure reduction. [12] [7]", "contents": "Vericiguat -- Adverse Effects. The most common adverse drug reactions of vericiguat\u00a0include\u00a0hypotension, syncope, and anemia. [2] Headache and postural dizziness reportedly could be due to vasodilation mediated by vericiguat. Diarrhea, nausea, and abdominal discomfort have been postulated due to smooth muscle relaxation. [11] Symptomatic hypotension, orthostatic hypotension, syncope, and anemia are some of the known side effects of vericiguat. [1] A mild increase in heart rate was observed, which\u00a0researchers considered the compensatory baroreflex due to vasodilation and blood pressure reduction. [12] [7]"}
{"id": "article-134517_20", "title": "Vericiguat -- Adverse Effects", "content": "Few subjects developed proteinuria, influenza, and nasopharyngitis during the drug trial, but no severe adverse event or death has been reported. Changes in vasoactive hormones for cGMP, plasma renin activity, and noradrenaline have been noted, but no changes in aldosterone activity, urine or serum electrolytes have been observed. Limited but consistent decrease in creatinine, urea, and uric acid was reported. [11]", "contents": "Vericiguat -- Adverse Effects. Few subjects developed proteinuria, influenza, and nasopharyngitis during the drug trial, but no severe adverse event or death has been reported. Changes in vasoactive hormones for cGMP, plasma renin activity, and noradrenaline have been noted, but no changes in aldosterone activity, urine or serum electrolytes have been observed. Limited but consistent decrease in creatinine, urea, and uric acid was reported. [11]"}
{"id": "article-134517_21", "title": "Vericiguat -- Adverse Effects", "content": "In contrast, one study\u00a0reported no significant difference in worsening renal function between vericiguat or placebo use. Therefore, Vericiguat might be beneficial in patients with severe heart failure and does not require decreasing or stopping the dose of vericiguat in patients with a mild increase in serum creatinine or potassium levels. [13] Vericiguat would be potentially useful to treat heart failure with reduced ejection fraction and improve the patient's quality of life. [14] [15]", "contents": "Vericiguat -- Adverse Effects. In contrast, one study\u00a0reported no significant difference in worsening renal function between vericiguat or placebo use. Therefore, Vericiguat might be beneficial in patients with severe heart failure and does not require decreasing or stopping the dose of vericiguat in patients with a mild increase in serum creatinine or potassium levels. [13] Vericiguat would be potentially useful to treat heart failure with reduced ejection fraction and improve the patient's quality of life. [14] [15]"}
{"id": "article-134517_22", "title": "Vericiguat -- Adverse Effects -- Drug-Drug Interactions", "content": "Administration of omeprazole with vericiguat reduced the absorption\u00a0of vericiguat. Magnesium hydroxide and aluminum hydroxide also\u00a0decreased the absorption of vericiguat. Drug-drug interaction study indicates that\u00a0vericiguat is a suitable drug for managing\u00a0patients with heart failure with\u00a0multiple comorbidities requiring polypharmacy. [9]", "contents": "Vericiguat -- Adverse Effects -- Drug-Drug Interactions. Administration of omeprazole with vericiguat reduced the absorption\u00a0of vericiguat. Magnesium hydroxide and aluminum hydroxide also\u00a0decreased the absorption of vericiguat. Drug-drug interaction study indicates that\u00a0vericiguat is a suitable drug for managing\u00a0patients with heart failure with\u00a0multiple comorbidities requiring polypharmacy. [9]"}
{"id": "article-134517_23", "title": "Vericiguat -- Contraindications", "content": "Vericiguat should be avoided in patients taking long-acting nitrates, soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5) inhibitors concerning hypotension and syncope.\u00a0Clinicians should also\u00a0avoid using the drug in patients with severe anemia\u00a0because of concerns of a decrease in hemoglobin level with vericiguat. [2] [10]", "contents": "Vericiguat -- Contraindications. Vericiguat should be avoided in patients taking long-acting nitrates, soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5) inhibitors concerning hypotension and syncope.\u00a0Clinicians should also\u00a0avoid using the drug in patients with severe anemia\u00a0because of concerns of a decrease in hemoglobin level with vericiguat. [2] [10]"}
{"id": "article-134517_24", "title": "Vericiguat -- Contraindications", "content": "Boxed Warning: Embryo-Fetal Toxicity: Animal reproduction studies suggest that vericiguat may cause fetal harm to a pregnant woman. Suggest females of reproductive age of the potential hazard to a fetus. Clinicians should order pregnancy tests before treatment with vericiguat. Advise females to use contraception during treatment and at least one month after the final dose of vericiguat.", "contents": "Vericiguat -- Contraindications. Boxed Warning: Embryo-Fetal Toxicity: Animal reproduction studies suggest that vericiguat may cause fetal harm to a pregnant woman. Suggest females of reproductive age of the potential hazard to a fetus. Clinicians should order pregnancy tests before treatment with vericiguat. Advise females to use contraception during treatment and at least one month after the final dose of vericiguat."}
{"id": "article-134517_25", "title": "Vericiguat -- Monitoring", "content": "The clinical team should monitor\u00a0blood pressure, heart rate, and hemoglobin are advised in patients treated with vericiguat. [1] [2] [10]", "contents": "Vericiguat -- Monitoring. The clinical team should monitor\u00a0blood pressure, heart rate, and hemoglobin are advised in patients treated with vericiguat. [1] [2] [10]"}
{"id": "article-134517_26", "title": "Vericiguat -- Monitoring", "content": "Monitor BNP or NT-proBNP levels to assess response to the therapy to vericiguat.\u00a0Monitor fluid intake and output,\u00a0body weight, and clinical\u00a0signs and symptoms of congestion and hypoperfusion in patients with heart failure. [6]", "contents": "Vericiguat -- Monitoring. Monitor BNP or NT-proBNP levels to assess response to the therapy to vericiguat.\u00a0Monitor fluid intake and output,\u00a0body weight, and clinical\u00a0signs and symptoms of congestion and hypoperfusion in patients with heart failure. [6]"}
{"id": "article-134517_27", "title": "Vericiguat -- Toxicity", "content": "Limited\u00a0information\u00a0is available about\u00a0toxicity in human patients treated with vericiguat. In the\u00a0clinical trial, doses up to 10 mg have been investigated. In a study of patients with HFpEF, multiple doses of vericiguat\u00a015 mg were investigated without toxicity. However, in the event of an overdose, hypotension may occur. There is no specific antidote for vericiguat toxicity. Symptomatic treatment should be provided.\u00a0Vericiguat is not removed\u00a0by hemodialysis\u00a0due to the high plasma protein binding(98%). [9]", "contents": "Vericiguat -- Toxicity. Limited\u00a0information\u00a0is available about\u00a0toxicity in human patients treated with vericiguat. In the\u00a0clinical trial, doses up to 10 mg have been investigated. In a study of patients with HFpEF, multiple doses of vericiguat\u00a015 mg were investigated without toxicity. However, in the event of an overdose, hypotension may occur. There is no specific antidote for vericiguat toxicity. Symptomatic treatment should be provided.\u00a0Vericiguat is not removed\u00a0by hemodialysis\u00a0due to the high plasma protein binding(98%). [9]"}
{"id": "article-134517_28", "title": "Vericiguat -- Enhancing Healthcare Team Outcomes", "content": "Heart failure remains a major burden in the US, with multiple patients at risk of death or recurrent hospitalization. An estimated 8 million people in the US will have heart failure by 2030. [16] Hence it is important to optimize heart failure therapy. GDMT (goal-directed medical therapy) for HFrEF\u00a0includes\u00a0beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors.\u00a0According to\u00a0ACC/AHA 2022 guidelines,\u00a0in\u00a0high-risk patients with HFrEF (Stage C) and\u00a0recent worsening of HF already on GDMT,\u00a0vericiguat\u00a0has an important role\u00a0in reducing HF\u00a0hospitalization and cardiovascular death. [6] VICTORIA\u00a0trial\u00a0has proven the efficacy and safety of vericiguat in patients with HFrEF. However, in the\u00a0VITALITY-HFpEF trial, treatment with vericiguat did not improve the physical limitation score of the Kansas City Cardiomyopathy Questionnaire\u00a0(KCCQ). [10]", "contents": "Vericiguat -- Enhancing Healthcare Team Outcomes. Heart failure remains a major burden in the US, with multiple patients at risk of death or recurrent hospitalization. An estimated 8 million people in the US will have heart failure by 2030. [16] Hence it is important to optimize heart failure therapy. GDMT (goal-directed medical therapy) for HFrEF\u00a0includes\u00a0beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors.\u00a0According to\u00a0ACC/AHA 2022 guidelines,\u00a0in\u00a0high-risk patients with HFrEF (Stage C) and\u00a0recent worsening of HF already on GDMT,\u00a0vericiguat\u00a0has an important role\u00a0in reducing HF\u00a0hospitalization and cardiovascular death. [6] VICTORIA\u00a0trial\u00a0has proven the efficacy and safety of vericiguat in patients with HFrEF. However, in the\u00a0VITALITY-HFpEF trial, treatment with vericiguat did not improve the physical limitation score of the Kansas City Cardiomyopathy Questionnaire\u00a0(KCCQ). [10]"}
{"id": "article-134517_29", "title": "Vericiguat -- Enhancing Healthcare Team Outcomes", "content": "Vericiguat is typically prescribed by clinicians (MD, DO, NP, PA) as part of the interprofessional healthcare team. The clinician plays the most crucial\u00a0role in the overall care of heart failure patients with multiple comorbidities. Consultation with a cardiologist or heart failure specialist is\u00a0highly recommended for high-risk patient populations for treatment optimization.\u00a0Pharmacists have an important role in medication reconciliation and adverse drug reaction counseling. Specialist nurses play an important role in\u00a0monitoring fluid status\u00a0for patients with heart failure and reporting any adverse effects of vericiguat therapy to clinicians. Critical care physicians and HF specialists are crucial in stabilizing patients with acute decompensated heart failure requiring vasopressors and inotropes.\u00a0Early hospital readmission in patients\u00a0with heart failure is quite common. In the United States,\u00a0approximately 30% of patients are re-hospitalized within 90 days of discharge.\u00a0Hence optimization of heart failure treatment is crucial at discharge, where\u00a0HF specialists\u00a0and pharmacists can play a crucial role. [17] In summary, healthcare professionals\u00a0have an essential role in educating patients regarding the importance of treatment of heart failure\u00a0with\u00a0GDMT, the role of vericiguat, and its adverse drug reactions. All interprofessional healthcare team members must have open lines of communication with the rest of the team to communicate any\u00a0patient status changes and arrange for therapy adjustments when needed.", "contents": "Vericiguat -- Enhancing Healthcare Team Outcomes. Vericiguat is typically prescribed by clinicians (MD, DO, NP, PA) as part of the interprofessional healthcare team. The clinician plays the most crucial\u00a0role in the overall care of heart failure patients with multiple comorbidities. Consultation with a cardiologist or heart failure specialist is\u00a0highly recommended for high-risk patient populations for treatment optimization.\u00a0Pharmacists have an important role in medication reconciliation and adverse drug reaction counseling. Specialist nurses play an important role in\u00a0monitoring fluid status\u00a0for patients with heart failure and reporting any adverse effects of vericiguat therapy to clinicians. Critical care physicians and HF specialists are crucial in stabilizing patients with acute decompensated heart failure requiring vasopressors and inotropes.\u00a0Early hospital readmission in patients\u00a0with heart failure is quite common. In the United States,\u00a0approximately 30% of patients are re-hospitalized within 90 days of discharge.\u00a0Hence optimization of heart failure treatment is crucial at discharge, where\u00a0HF specialists\u00a0and pharmacists can play a crucial role. [17] In summary, healthcare professionals\u00a0have an essential role in educating patients regarding the importance of treatment of heart failure\u00a0with\u00a0GDMT, the role of vericiguat, and its adverse drug reactions. All interprofessional healthcare team members must have open lines of communication with the rest of the team to communicate any\u00a0patient status changes and arrange for therapy adjustments when needed."}
{"id": "article-134517_30", "title": "Vericiguat -- Enhancing Healthcare Team Outcomes", "content": "A systemic review and meta-analysis involving\u00a019 randomized controlled trials showed that a multidisciplinary,\u00a0interprofessional approach between primary care physicians, specialists, nurses, social workers, cardiologists, and pharmacist is crucial. Meta-analysis\u00a0results indicated\u00a0a\u00a0significant reduction in mortality, heart failure readmissions, and all-cause readmissions involving the primary care provider model. [18] [Level 1]", "contents": "Vericiguat -- Enhancing Healthcare Team Outcomes. A systemic review and meta-analysis involving\u00a019 randomized controlled trials showed that a multidisciplinary,\u00a0interprofessional approach between primary care physicians, specialists, nurses, social workers, cardiologists, and pharmacist is crucial. Meta-analysis\u00a0results indicated\u00a0a\u00a0significant reduction in mortality, heart failure readmissions, and all-cause readmissions involving the primary care provider model. [18] [Level 1]"}
{"id": "article-134517_31", "title": "Vericiguat -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Vericiguat -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}